816.2K XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Greg Keenan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.23 per share. | 07 Mar 2025 | 8,305 | 153,484 (0%) | 0% | 8.2 | 68,350 | Common Stock |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.85 per share. | 28 Feb 2025 | 399,280 | 8,828,780 (10%) | 0% | 7.9 | 3,134,348 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.97 per share. | 28 Feb 2025 | 100,720 | 8,929,500 (10%) | 0% | 8.0 | 802,738 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.02 per share. | 28 Feb 2025 | 351,962 | 9,281,462 (10%) | 0% | 8.0 | 2,822,735 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 28 Feb 2025 | 148,038 | 9,429,500 (11%) | 0% | 8 | 1,184,304 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 7.92 per share. | 28 Feb 2025 | 500,000 | 9,929,500 (11%) | 0% | 7.9 | 3,960,000 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.09 per share. | 28 Feb 2025 | 100,000 | 10,029,500 (11%) | 0% | 8.1 | 809,000 | Common Shares |
| Matthew Donley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 82,781 | 669,791 (0%) | 0% | 0 | Common Stock | |
| Matthew Donley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 135,567 | 805,358 (0%) | 0% | 0 | Common Stock | |
| Matthew Donley | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 28 Feb 2025 | 65,902 | 739,456 (0%) | 0% | 8 | 527,216 | Common Stock |
| Matthew Donley | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 28 Feb 2025 | 58,991 | 680,465 (0%) | 0% | 7.9 | 467,209 | Common Stock |
| Matthew Donley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 126,416 | 126,416 | - | - | Employee Stock Option (right to buy) | |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 81,457 | 580,663 (0%) | 0% | 0 | Common Stock | |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 114,711 | 695,374 (0%) | 0% | 0 | Common Stock | |
| Joseph M. Miller | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 28 Feb 2025 | 61,859 | 633,515 (0%) | 0% | 8 | 494,872 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 28 Feb 2025 | 56,154 | 577,361 (0%) | 0% | 7.9 | 444,740 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 124,393 | 124,393 | - | - | Employee Stock Option (right to buy) | |
| Stephen P. Robertson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 84,106 | 529,349 (0%) | 0% | 0 | Common Stock | |
| Stephen P. Robertson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 102,406 | 631,755 (0%) | 0% | 0 | Common Stock | |
| Stephen P. Robertson | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 28 Feb 2025 | 64,872 | 566,883 (0%) | 0% | 8 | 518,976 | Common Stock |
| Stephen P. Robertson | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 28 Feb 2025 | 57,607 | 509,276 (0%) | 0% | 7.9 | 456,247 | Common Stock |
| Stephen P. Robertson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 128,438 | 128,438 | - | - | Employee Stock Option (right to buy) | |
| Greg Keenan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 62,583 | 174,028 (0%) | 0% | 0 | Common Stock | |
| Greg Keenan | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 28 Feb 2025 | 12,239 | 161,789 (0%) | 0% | 8 | 97,912 | Common Stock |
| Greg Keenan | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 95,570 | 95,570 | - | - | Employee Stock Option (right to buy) | |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.09 per share. | 05 Dec 2024 | 500,000 | 8,429,500 (9%) | 0% | 9.1 | 4,545,000 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 9.01 per share. | 05 Dec 2024 | 400,000 | 7,929,500 (9%) | 0% | 9.0 | 3,604,000 | Common Shares |
| Kevin C. Tang | Director | Purchase of securities on an exchange or from another person at price $ 8.91 per share. | 05 Dec 2024 | 300,000 | 7,529,500 (8%) | 0% | 8.9 | 2,673,000 | Common Shares |
| Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 20,631 | 20,631 (0%) | 0% | 0 | Common Shares | |
| Craig A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 31,688 | 31,688 | - | - | Director Stock Option (right to buy) | |
| Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 25,491 (0%) | 0% | 0 | Common Shares | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 25,053 (0%) | 0% | 0 | Common Shares | |
| Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 24,807 (0%) | 0% | 0 | Common Shares | |
| Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| David R.W. Jayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| David R.W. Jayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 56,499 (0%) | 0% | 0 | Common Shares | |
| Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | |
| Jeffrey Allen Bailey | Director | Sale of securities on an exchange or to another person at price $ 8.43 per share. | 08 Nov 2024 | 4,557 | 13,356 (0%) | 0% | 8.4 | 38,416 | Common Stock |
| Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | |
| Karen L. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | |
| Karen L. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | |
| Karen L. Smith | Director | Sale of securities on an exchange or to another person at price $ 8.43 per share. | 08 Nov 2024 | 5,241 | 12,672 (0%) | 0% | 8.4 | 44,182 | Common Stock |
| Scott Michael Habig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 5.31 per share. | 06 Aug 2024 | 18,249 | 456,338 (0%) | 0% | 5.3 | 96,902 | Common Stock |
| R. Hector Mackay-Dunn | Director | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 21 May 2024 | 5,630 | 18,595 (0%) | 0% | 5.7 | 32,316 | Common Stock |
| Jill D. Leversage | Director | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 21 May 2024 | 5,610 | 12,918 (0%) | 0% | 5.7 | 32,201 | Common Stock |
| David R.W. Jayne | Director | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 21 May 2024 | 4,946 | 44,364 (0%) | 0% | 5.7 | 28,390 | Common Stock |
| Daniel G. Billen | Director | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 21 May 2024 | 5,252 | 28,141 (0%) | 0% | 5.7 | 30,146 | Common Stock |
| Brinda Balakrishnan | Director | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 21 May 2024 | 520 | 17,523 (0%) | 0% | 5.7 | 2,985 | Common Stock |
| Matthew Donley | EVP, Ops & Strategy | Sale of securities on an exchange or to another person at price $ 5.51 per share. | 06 Mar 2024 | 40,665 | 584,072 (0%) | 0% | 5.5 | 224,064 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 06 Mar 2024 | 34,811 | 495,928 (0%) | 0% | 5.6 | 194,942 | Common Stock |
| Stephen P. Robertson | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 06 Mar 2024 | 57,745 | 443,824 (0%) | 0% | 5.6 | 323,372 | Common Stock |
| Scott Michael Habig | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 06 Mar 2024 | 17,777 | 474,587 (0%) | 0% | 5.6 | 99,551 | Common Stock |
| Knappertz Volker | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 27 Feb 2024 | 4,930 | 319,128 (0%) | 0% | 6.1 | 30,073 | Common Stock |
| Michael Scott Habig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 195,512 | 508,231 (0%) | 0% | 0 | Common Stock | |
| Michael Habig Scott | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 5.48 per share. | 20 Feb 2024 | 15,867 | 492,364 (0%) | 0% | 5.5 | 86,951 | Common Stock |
| Miller Joseph M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 196,153 | 530,739 (0%) | 0% | 0 | Common Stock | |
| P. Robertson Stephen | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 194,230 | 501,569 (0%) | 0% | 0 | Common Stock | |
| Donley Matthew | EVP, Ops & Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 216,666 | 624,737 (0%) | 0% | 0 | Common Stock | |
| Volker Knappertz | EVP, Research and Development | Sale of securities on an exchange or to another person at price $ 5.48 per share. | 20 Feb 2024 | 25,146 | 324,058 (0%) | 0% | 5.5 | 137,800 | Common Stock |
| Robert T. Foster | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2023 | 20,383 | 20,383 | - | - | Restricted Stock Units | |
| T. Foster Robert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2023 | 32,900 | 32,900 | - | - | Stock Option (right to buy) | |
| Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | |
| Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | |
| Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | |
| Karen L. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | |
| George Mclean Milne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 78,733 (0%) | 0% | - | Common Stock | |
| George Mclean Milne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 12,233 (0%) | 0% | - | Common Stock | |
| Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 10.58 per share. | 18 May 2023 | 272 | 11,961 (0%) | 0% | 10.6 | 2,878 | Common Stock |
| R. Hector Mackay-Dunn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| R. Hector Mackay-Dunn | Director | Sale of securities on an exchange or to another person at price $ 11.26 per share. | 18 May 2023 | 4,818 | 24,225 (0%) | 0% | 11.3 | 54,251 | Common Stock |
| R. Hector Mackay-Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,310 | 29,043 (0%) | 0% | 0 | Common Stock | |
| R. Hector Mackay-Dunn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 19,733 (0%) | 0% | - | Common Stock | |
| R. Hector Mackay-Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 15,234 | 15,234 | - | - | Stock Option (right to buy) | |
| Jill D. Leversage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 14,033 (0%) | 0% | - | Common Stock | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,310 | 23,343 (0%) | 0% | 0 | Common Stock | |
| Jill D. Leversage | Director | Sale of securities on an exchange or to another person at price $ 11.26 per share. | 18 May 2023 | 4,815 | 18,528 (0%) | 0% | 11.3 | 54,217 | Common Stock |
| Jill D. Leversage | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 15,234 | 15,234 | - | - | Stock Option (right to buy) | |
| David R.W. Jayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 15,234 | 15,234 | - | - | Stock Option (right to buy) | |
| David R.W. Jayne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 48,733 (0%) | 0% | - | Common Stock | |
| David R.W. Jayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,310 | 58,043 (0%) | 0% | 0 | Common Stock | |
| David R.W. Jayne | Director | Sale of securities on an exchange or to another person at price $ 11.26 per share. | 18 May 2023 | 8,733 | 49,310 (0%) | 0% | 11.3 | 98,334 | Common Stock |
| David R.W. Jayne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Daniel G. Billen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 28,733 (0%) | 0% | - | Common Stock | |
| Daniel G. Billen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Daniel G. Billen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 15,234 | 15,234 | - | - | Stock Option (right to buy) | |
| Daniel G. Billen | Director | Sale of securities on an exchange or to another person at price $ 11.26 per share. | 18 May 2023 | 4,650 | 33,393 (0%) | 0% | 11.3 | 52,359 | Common Stock |
| Daniel G. Billen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,310 | 38,043 (0%) | 0% | 0 | Common Stock | |
| Brinda Balakrishnan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 0 | - | - | Restricted Stock Units | |
| Brinda Balakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,310 | 18,043 (0%) | 0% | 0 | Common Stock | |
| Brinda Balakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 15,234 | 15,234 | - | - | Stock Option (right to buy) | |
| Brinda Balakrishnan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 8,733 | 8,733 (0%) | 0% | - | Common Stock | |
| George Mclean Milne | Director | Purchase of securities on an exchange or from another person at price $ 8.91 per share. | 02 Mar 2023 | 20,000 | 70,000 (0%) | 0% | 8.9 | 178,284 | Common Stock |
| Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 107,202 | 259,162 (0%) | 0% | - | Common Stock | |
| Matthew Donley | EVP, Ops & Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 271,134 | 403,141 (0%) | 0% | - | Common Stock | |
| Volker Knappertz | EVP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 191,462 | 344,274 (0%) | 0% | 0 | Common Stock | |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 229,421 | 342,510 (0%) | 0% | - | Common Stock | |
| Joseph M. Miller | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 02 Mar 2023 | 11,296 | 331,214 (0%) | 0% | 8.9 | 100,986 | Common Stock |
| Stephen P. Robertson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 204,810 | 322,766 (0%) | 0% | - | Common Stock | |
| Stephen P. Robertson | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 8.94 per share. | 02 Mar 2023 | 19,402 | 303,364 (0%) | 0% | 8.9 | 173,454 | Common Stock |
| Scott Michael Habig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 170,188 | 312,719 (0%) | 0% | - | Common Stock | |
| Stephen Robertson P. | EVP, General Counsel | Sale of securities on an exchange or to another person at price $ 8.78 per share. | 02 Mar 2023 | 19,644 | 303,122 (0%) | 0% | 8.8 | 172,474 | Common Stock |
| Joseph Miller M. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.78 per share. | 02 Mar 2023 | 11,398 | 331,112 (0%) | 0% | 8.8 | 100,074 | Common Stock |
| Matthew Donley | Ex VP, Internal Operations | Purchase of securities on an exchange or from another person at price $ 4.66 per share. | 21 Nov 2022 | 10,000 | 27,927 (0%) | 0% | 4.7 | 46,600 | Common Stock |
| Scott Michael Habig | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 5.02 per share. | 09 Nov 2022 | 5,000 | 5,000 (0%) | 0% | 5.0 | 25,075 | Common Stock |
| Michael R. Martin | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 5.16 per share. | 07 Nov 2022 | 30,000 | 89,512 (0%) | 0% | 5.2 | 154,800 | Common Stock |
| Scott Michael Habig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 231,203 | 231,203 | - | - | Stock Option (right to buy) | |
| Scott Michael Habig | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 137,531 | 137,531 | - | - | Restricted Stock Units | |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| George Mclean Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| R. Hector Mackay-Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| R. Hector Mackay-Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| David R.W. Jayne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.62 per share. | 18 May 2022 | 10,000 | 40,000 (0%) | 0% | 3.6 | 36,200 | Common Stock |
| David R.W. Jayne | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2022 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Daniel G. Billen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| Daniel G. Billen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Brinda Balakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,733 | 8,733 | - | - | Restricted Stock Unit | |
| Brinda Balakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 14,612 | 14,612 | - | - | Stock Option (right to buy) | |
| R. Hector Mackay-Dunn | Director | Purchase of securities on an exchange or from another person at price $ 11.00 per share. | 09 Mar 2022 | 5,000 | 11,000 (0%) | 0% | 11.0 | 54,985 | Common Stock |
| George Mclean Milne | Director | Purchase of securities on an exchange or from another person at price $ 10.82 per share. | 04 Mar 2022 | 5,000 | 50,000 (0%) | 0% | 10.8 | 54,100 | Common Stock |
| Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 106,838 | 106,838 | - | - | Stock Option (right to buy) | |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 4,849 | 69,379 (0%) | 0% | 12.0 | 58,236 | Common Stock |
| Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 74,228 (0%) | 0% | 0 | Common Stock | |
| Robert Huizinga | EVP of Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 62,448 | 62,448 | - | - | Restricted Stock Unit | |
| Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 64,361 (0%) | 0% | 0 | Common Stock | |
| Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 62,448 | 62,448 | - | - | Restricted Stock Unit | |
| Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 106,838 | 106,838 | - | - | Stock Option (right to buy) | |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 4,849 | 59,512 (0%) | 0% | 12.0 | 58,236 | Common Stock |
| Neil Solomons | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 124,644 | 124,644 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 95,799 (0%) | 0% | 0 | Common Stock | |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 4,846 | 90,953 (0%) | 0% | 12.0 | 58,200 | Common Stock |
| Neil Solomons | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 72,856 | 72,856 | - | - | Restricted Stock Unit | |
| Matthew Donley | Ex VP, Internl Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 19,276 (0%) | 0% | 0 | Common Stock | |
| Matthew Donley | Ex VP, Internl Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 178,063 | 178,063 | - | - | Stock Option (right to buy) | |
| Matthew Donley | Ex VP, Internl Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 104,080 | 104,080 | - | - | Restricted Stock Unit | |
| Matthew Donley | Ex VP, Internl Operations | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 3,052 | 16,224 (0%) | 0% | 12.0 | 36,655 | Common Stock |
| Massimilano Colao | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 3,205 | 13,495 (0%) | 0% | 12.0 | 38,492 | Common Stock |
| Massimilano Colao | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 178,063 | 178,063 | - | - | Stock Option (right to buy) | |
| Massimilano Colao | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 104,080 | 104,080 | - | - | Restricted Stock Unit | |
| Massimilano Colao | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 16,700 (0%) | 0% | 0 | Common Stock | |
| Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 22.58 per share. | 03 Jan 2022 | 39,366 | 4,134 (0%) | 0% | 22.6 | 888,884 | Common Stock |
| Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 40,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Joseph P. Hagan | Director | Sale of securities on an exchange or to another person at price $ 23.29 per share. | 03 Jan 2022 | 634 | 3,500 (0%) | 0% | 23.3 | 14,766 | Common Stock |
| Joseph P. Hagan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.08 per share. | 03 Jan 2022 | 40,000 | 43,500 (0%) | 0% | 5.1 | 203,200 | Common Stock |
| Jill D. Leversage | Director | Purchase of securities on an exchange or from another person at price $ 20.04 per share. | 13 Dec 2021 | 1,600 | 5,300 (0%) | 0% | 20.0 | 32,064 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.50 per share. | 09 Nov 2021 | 11,000 | 55,861 (0%) | 0% | 29.5 | 324,500 | Common Shares |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 28.82 per share. | 09 Nov 2021 | 29,000 | 66,861 (0%) | 0% | 28.8 | 835,780 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.38 per share. | 09 Nov 2021 | 29,000 | 95,861 (0%) | 0% | 18.4 | 533,020 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 29,000 | 27,900 | - | - | Stock Option (right to buy) | |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.26 per share. | 09 Nov 2021 | 50,000 | 76,861 (0%) | 0% | 31.3 | 1,563,000 | Common Shares |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.17 per share. | 09 Nov 2021 | 50,000 | 126,861 (0%) | 0% | 30.2 | 1,508,500 | Common Shares |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.55 per share. | 09 Nov 2021 | 10,000 | 66,861 (0%) | 0% | 30.6 | 305,500 | Common Shares |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 09 Nov 2021 | 30,000 | 187,299 (0%) | 0% | 5.3 | 159,000 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.17 per share. | 09 Nov 2021 | 50,000 | 87,299 (0%) | 0% | 30.2 | 1,508,500 | Common Shares |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.06 per share. | 09 Nov 2021 | 70,000 | 157,299 (0%) | 0% | 6.1 | 424,200 | Common Stock |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 100,000 | 0 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 30,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 70,000 | 0 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.89 per share. | 09 Nov 2021 | 100,000 | 87,299 (0%) | 0% | 28.9 | 2,889,000 | Common Stock |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 09 Nov 2021 | 100,000 | 187,299 (0%) | 0% | 5.3 | 530,000 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.55 per share. | 09 Nov 2021 | 10,000 | 87,299 (0%) | 0% | 30.6 | 305,500 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.17 per share. | 09 Nov 2021 | 90,000 | 97,299 (0%) | 0% | 31.2 | 2,805,300 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.64 per share. | 01 Nov 2021 | 45,000 | 176,861 (0%) | 0% | 31.6 | 1,423,800 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 01 Nov 2021 | 45,000 | 221,861 (0%) | 0% | 3.2 | 144,000 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.64 per share. | 01 Nov 2021 | 45,000 | 137,299 (0%) | 0% | 31.6 | 1,423,800 | Common Stock |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 45,000 | 130,000 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 01 Nov 2021 | 45,000 | 182,299 (0%) | 0% | 5.3 | 238,500 | Common Stock |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 29.75 per share. | 25 Oct 2021 | 130,000 | 65,728 (0%) | 0% | 29.8 | 3,867,500 | Common Stock |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 95,000 | 3,864 | - | - | Stock Option (right to buy) | |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 25 Oct 2021 | 95,000 | 195,728 (0%) | 0% | 3.2 | 304,000 | Common Stock |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 21 Sep 2021 | 11,136 | 133,228 (0%) | 0% | 3.2 | 35,635 | Common Stock |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 11,136 | 98,864 | - | - | Stock Option (right to buy) | |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 16,000 | 0 | - | - | Stock Option (right to buy) | |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 21 Sep 2021 | 5,364 | 100,728 (0%) | 0% | 23.7 | 126,912 | Common Stock |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 21 Sep 2021 | 27,136 | 106,092 (0%) | 0% | 24.1 | 652,621 | Common Stock |
| Robert Huizinga | EVP of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.63 per share. | 21 Sep 2021 | 16,000 | 122,092 (0%) | 0% | 2.6 | 42,080 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.60 per share. | 20 Sep 2021 | 16,000 | 176,861 (0%) | 0% | 21.6 | 345,600 | Common Shares |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 10,000 | 56,900 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 70,000 | 0 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 7,500 | 0 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 28,500 | 7,500 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 24.02 per share. | 20 Sep 2021 | 87,500 | 176,861 (0%) | 0% | 24.0 | 2,101,750 | Common Shares |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.38 per share. | 20 Sep 2021 | 10,000 | 264,361 (0%) | 0% | 18.4 | 183,800 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.06 per share. | 20 Sep 2021 | 70,000 | 254,361 (0%) | 0% | 6.1 | 424,200 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 20 Sep 2021 | 7,500 | 184,361 (0%) | 0% | 5.3 | 39,750 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.71 per share. | 20 Sep 2021 | 12,500 | 192,861 (0%) | 0% | 21.7 | 271,375 | Common Shares |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 20 Sep 2021 | 28,500 | 205,361 (0%) | 0% | 5.3 | 151,050 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 14 Sep 2021 | 44,000 | 220,861 (0%) | 0% | 5.3 | 233,200 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2021 | 44,000 | 36,000 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.80 per share. | 14 Sep 2021 | 30,000 | 176,861 (0%) | 0% | 21.8 | 654,000 | Common Shares |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.73 per share. | 14 Sep 2021 | 14,000 | 206,861 (0%) | 0% | 21.7 | 304,220 | Common Shares |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 19.83 per share. | 10 Sep 2021 | 5,000 | 133,592 (0%) | 0% | 19.8 | 99,150 | Common Stock |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 10 Sep 2021 | 22,500 | 106,092 (0%) | 0% | 21.8 | 489,375 | Common Stock |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 19.76 per share. | 10 Sep 2021 | 5,000 | 128,592 (0%) | 0% | 19.8 | 98,800 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 25,000 | 125,000 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.19 per share. | 10 Sep 2021 | 90,000 | 176,861 (0%) | 0% | 21.2 | 1,907,217 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 10 Sep 2021 | 45,000 | 266,861 (0%) | 0% | 3.2 | 144,000 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 10 Sep 2021 | 45,000 | 221,861 (0%) | 0% | 5.3 | 238,500 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 19.80 per share. | 10 Sep 2021 | 25,000 | 176,861 (0%) | 0% | 19.8 | 495,000 | Common Shares |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 10 Sep 2021 | 25,000 | 201,861 (0%) | 0% | 5.3 | 132,500 | Common Shares |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 45,000 | 45,000 | - | - | Option Grant (right to buy) | |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 45,000 | 80,000 | - | - | Option Grant (right to buy) | |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 10 Sep 2021 | 150,000 | 287,299 (0%) | 0% | 3.2 | 480,000 | Common Shares |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 150,000 | 2,000 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.84 per share. | 10 Sep 2021 | 150,000 | 137,299 (0%) | 0% | 19.8 | 2,976,000 | Common Shares |
| Robert Huizinga | EVP of Research | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 07 Sep 2021 | 5,000 | 138,592 (0%) | 0% | 18.3 | 91,500 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.10 per share. | 07 Sep 2021 | 7,500 | 176,861 (0%) | 0% | 18.1 | 135,750 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 26 Aug 2021 | 22,500 | 184,361 (0%) | 0% | 17.8 | 400,725 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.85 per share. | 25 Aug 2021 | 5,000 | 137,299 (0%) | 0% | 15.9 | 79,250 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 09 Aug 2021 | 5,000 | 206,861 (0%) | 0% | 16.0 | 80,050 | Common Stock |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.03 per share. | 09 Aug 2021 | 45,000 | 142,299 (0%) | 0% | 16.0 | 721,350 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.86 per share. | 28 Jul 2021 | 5,000 | 211,861 (0%) | 0% | 13.9 | 69,300 | Common Stock |
| Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.76 per share. | 22 Jun 2021 | 5,000 | 216,861 (0%) | 0% | 13.8 | 68,800 | Common Stock |
| George M. Milne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Timothy P. Walbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Joseph P. Hagan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| R. Hector Mackay-Dunn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Jill D. Leversage | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| David R.W. Jayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Daniel G. Billen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 31,347 | 31,347 | - | - | Stock Option (right to buy) | |
| Brinda Balakrishnan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 53,291 | 53,291 | - | - | Stock Option (right to buy) | |
| R. Hector Mackay-Dunn | Director | Purchase of securities on an exchange or from another person at price $ 11.14 per share. | 11 May 2021 | 1,000 | 3,000 (0%) | 0% | 11.1 | 11,140 | Common Stock |
| R. Hector Mackay-Dunn | Director | Purchase of securities on an exchange or from another person at price $ 11.28 per share. | 11 May 2021 | 1,600 | 6,000 (0%) | 0% | 11.3 | 18,040 | Common Stock |
| R. Hector Mackay-Dunn | Director | Purchase of securities on an exchange or from another person at price $ 11.26 per share. | 11 May 2021 | 1,400 | 4,400 (0%) | 0% | 11.3 | 15,764 | Common Stock |
| R. Hector Mackay-Dunn | Director | Purchase of securities on an exchange or from another person at price $ 11.17 per share. | 11 May 2021 | 500 | 2,000 (0%) | 0% | 11.2 | 5,585 | Common Stock |
| Jill D. Leversage | Director | Purchase of securities on an exchange or from another person at price $ 10.96 per share. | 11 May 2021 | 2,500 | 3,700 (0%) | 0% | 11.0 | 27,389 | Common Stock |
| Robert Huizinga | Ex Vice President of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| Robert Huizinga | Ex Vice President of Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.02 per share. | 11 May 2021 | 40,000 | 143,592 (0%) | 0% | 3.0 | 120,800 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.02 per share. | 11 May 2021 | 20,000 | 221,861 (0%) | 0% | 3.0 | 60,400 | Common Stock |
| Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 20,000 | 0 | - | - | Option Grant (right to buy) | |
| Matthew Donley | Ex VP, Internl Operations | Purchase of securities on an exchange or from another person at price $ 10.07 per share. | 11 May 2021 | 9,900 | 9,900 (0%) | 0% | 10.1 | 99,739 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.74 per share. | 11 May 2021 | 1,000 | 1,000 (0%) | 0% | 9.7 | 9,740 | Common Stock |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2021 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| Neil Solomons | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.49 per share. | 12 Mar 2021 | 40,000 | 187,299 (0%) | 0% | 13.5 | 539,600 | Common Stock |
| Neil Solomons | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.02 per share. | 12 Mar 2021 | 40,000 | 227,299 (0%) | 0% | 3.0 | 120,800 | Common Stock |
| George M. Milne | Director | Purchase of securities on an exchange or from another person at price $ 13.00 per share. | 05 Mar 2021 | 5,000 | 45,000 (0%) | 0% | 13 | 65,000 | Common Stock |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.06 per share. | 29 Jan 2021 | 30,000 | 80,000 (0%) | 0% | 6.1 | 181,800 | Common Shares |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 15,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 30,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2021 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 29 Jan 2021 | 15,000 | 95,000 (0%) | 0% | 6.4 | 96,300 | Common Shares |
| Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.44 per share. | 29 Jan 2021 | 50,000 | 50,000 (0%) | 0% | 5.4 | 272,000 | Common Shares |
| Jill D. Leversage | Director | Purchase of securities on an exchange or from another person at price $ 16.03 per share. | 29 Jan 2021 | 400 | 400 (0%) | 0% | 16.0 | 6,412 | Common Shares |
| Jill D. Leversage | Director | Purchase of securities on an exchange or from another person at price $ 16.03 per share. | 29 Jan 2021 | 1,200 | 1,200 (0%) | 0% | 16.0 | 19,236 | Common Stock |
| Stephen P. Robertson | EVP, General Counsel | Purchase of securities on an exchange or from another person at price $ 16.14 per share. | 28 Jan 2021 | 900 | 2,720 (0%) | 0% | 16.1 | 14,526 | Common Stock |